1. What’s happening? Curexo’s upcoming IR

Curexo will hold an Investor Relations (IR) session on September 2nd. The event will include a company overview, business performance updates, and a Q&A session.

2. Why is it important? Assessing Curexo’s Present and Future

This IR is the first official communication channel for investors since Curexo’s Q2 earnings release. It’s a crucial opportunity to gain insights into key investment points like the growth potential of the medical robot business, addressing concerns about declining sales, and future business strategies.

3. Curexo Q2 2025 Earnings Analysis: Light and Shadow

  • Positive Factors:
    • Return to operating profit (KRW 637 million)
    • ‘Cuvis-Joint’ medical robot receives Japanese PMDA approval
    • Stable financial structure (Debt ratio of 10.71%)
  • Negative Factors:
    • Total sales decreased by 34.3% YoY
    • Trading business sales decreased by 46.4%
    • High proportion of related party transactions

4. So, what should investors do? Action Plan

Carefully review the IR information and seek answers to the following questions. Can Curexo overcome declining sales and increase corporate value through growth in the medical robot business? Pay close attention to the specific strategies and figures presented at the IR.

  • Is the plan to improve profitability in the medical robot business concrete?
  • What are the sales diversification and overseas market expansion strategies?
  • Are there plans to reduce dependence on related party transactions?

5. Post-IR Stock Price Outlook: Expert Predictions

Analysts are focusing on Curexo’s growth potential while expressing concerns about short-term sales decline and profitability improvement challenges. The solutions presented during this IR are expected to determine the future direction of the stock price.